Sana Biotechnology, Inc. $SANA Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. reduced its stake in Sana Biotechnology by 44.9%, selling 451,246 shares and retaining approximately 0.25% of the company, worth $930,000.
• Institutional investors own 88.23% of Sana Biotechnology, with notable increases from firms such as Northern Trust Corp and Jane Street Group LLC in the last quarter.
• Sana Biotechnology's stock opened at $3.25 and has a 1-year price range of $1.26 to $7.30, with analysts rating it a "Buy" and an average price target of $8.00.

Goldman Sachs Group Inc. reduced its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 44.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 553,405 shares of the company's stock after selling 451,246 shares during the period. Goldman Sachs Group Inc. owned approximately 0.25% of Sana Biotechnology worth $930,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SANA. Northern Trust Corp grew its position in Sana Biotechnology by 5.3% during the 4th quarter. Northern Trust Corp now owns 1,188,346 shares of the company's stock worth $1,937,000 after purchasing an additional 60,004 shares during the period. Jane Street Group LLC grew its position in Sana Biotechnology by 287.2% during the 4th quarter. Jane Street Group LLC now owns 367,855 shares of the company's stock worth $600,000 after purchasing an additional 272,862 shares during the period. Ameriprise Financial Inc. acquired a new stake in Sana Biotechnology during the 4th quarter worth about $29,000. BNP Paribas Financial Markets acquired a new stake in Sana Biotechnology during the 4th quarter worth about $34,000. Finally, Bank of America Corp DE grew its position in Sana Biotechnology by 11.3% during the 4th quarter. Bank of America Corp DE now owns 1,131,813 shares of the company's stock worth $1,845,000 after purchasing an additional 115,347 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

SANA opened at $3.25 on Tuesday. The company's 50 day simple moving average is $3.63 and its two-hundred day simple moving average is $2.74. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $7.30. The firm has a market capitalization of $772.88 million, a price-to-earnings ratio of -3.07 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. On average, equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price target on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Morgan Stanley started coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $8.00.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.